Nuvalent’s options story has advanced again. Earlier coverage on the site tracked the June 9 takeover agreement and the later tender-offer phase. Nasdaq’s July 13 corporate-actions alert adds a more operational milestone: July 14, 2026 is now the anticipated last trading day for NUVL, the stock is expected to be halted after the after-hours session at around 7:50 p.m. ET on July 14, the merger is tentatively scheduled to close before the market open on July 15, and the stock is slated to be suspended effective July 16 if the transaction closes as planned.
That is a distinct options phase. Once a cash deal reaches an explicit last-trading-date and halt schedule, the important question is no longer only how a tender offer changes time value. The question becomes how traders manage the final live stock session, what assignment and exercise risk still exists before the halt, and what to watch for if OCC later publishes the final cash-settlement terms.
This article is for market commentary and options education only. It is not financial advice, investment advice, trading advice, or a recommendation to buy or sell any security or options contract. Options trading involves risk and is not suitable for all investors. See the site’s risk disclosure.
What changed on July 13
Nasdaq’s alert tightened the event calendar in four ways:
| Item | Newly stated timing |
|---|---|
| Tender offer expiration | One minute after 11:59 p.m. ET on July 14, 2026, unless extended or terminated |
| Anticipated last trading day for NUVL stock | July 14, 2026 |
| Anticipated halt timing | Immediately after the after-hours session at around 7:50 p.m. ET on July 14 |
| Anticipated suspension date | July 16, 2026, if the merger closes as planned |
Nasdaq also repeated the deal consideration at USD 124.00 per share in cash.
That is more operationally useful than the earlier tender-offer article alone. The site’s prior Nuvalent tender-offer phase article explained why a visible cash-offer clock matters. This new phase goes one step closer to the end state by telling traders when normal stock trading is expected to stop.
Why This Matters For Options Traders
The cleanest way to read NUVL now is as a final-session merger instrument, not a normal biotech trading vehicle.
1. The stock’s last live session matters more than the headline cash price
In a generic cash-deal phase, traders can still think in terms of spread behavior over days or weeks. Once Nasdaq assigns an anticipated last trading day, that flexibility shrinks. If you still have short-dated optionality, the difference between “the deal should close soon” and “the stock is expected to stop trading after tomorrow’s post-close session” is meaningful.
That matters because option positions can still carry extrinsic value, assignment risk, and execution friction right up to the halt window. A final-session setup is more about time compression and contract handling than about a fresh opinion on Nuvalent’s business.
2. A halt schedule is not the same thing as the final OCC adjustment memo
This is the most important boundary to keep clear. Nasdaq’s alert tells traders when NUVL stock is expected to stop trading and be suspended. It does not itself provide the final OCC contract-adjustment terms for listed options after the merger closes.
That means traders should separate two steps:
- the exchange-level trading halt and suspension schedule for the stock
- the later OCC memo, if and when published, that tells the options market whether contracts become cash-settled, whether expirations are accelerated, and what the final deliverable or exercise-by-exception framework will be
If you want the background mechanics before the end-state memo arrives, the best refreshers are cash-settled vs physically-settled options explained, how options pricing works: intrinsic value vs time value, and options expiration, assignment, and exercise explained.
3. Assignment discipline still matters before the halt
Traders sometimes assume that once a merger looks nearly done, assignment risk stops mattering. That is wrong. If calls or puts are in the money and extrinsic value gets thin enough, exercise decisions can still happen before the stock halts. A short options position is still a short options position until the relevant contract terms change or the position is closed.
That is why early assignment risk in options trading: when and why it happens stays relevant even in a cash-deal name. The issue is not whether Nuvalent is still a growth-stock story. The issue is whether your position still exposes you to exercise, assignment, or awkward timing into a final session.
4. Liquidity can become less intuitive even before any final contract adjustment
The most visible option series can remain tradable while still becoming harder to interpret cleanly. Bid-ask spreads, residual time value, and the relationship between intrinsic value and quoted premium can all behave differently when the underlying is no longer being valued on open-ended stand-alone fundamentals.
That does not guarantee mispricing. It does mean execution quality matters more, especially for traders who are still thinking about NUVL the way they would think about an ordinary biotech catalyst name.
What is confirmed, and what is still open
Confirmed facts
- Nasdaq says the GSK tender offer is scheduled to expire one minute after 11:59 p.m. ET on July 14, 2026, unless extended or terminated.
- Nasdaq says July 14, 2026 is the anticipated last trading day for
NUVL. - Nasdaq says the stock is expected to be halted immediately following the after-hours session at around 7:50 p.m. ET on July 14.
- Nasdaq says the merger is tentatively scheduled to close before the market open on July 15, 2026 and that the stock would be suspended effective July 16, 2026 if closing occurs as planned.
- The merger consideration remains USD 124.00 in cash per share.
Interpretation
- Near-dated
NUVLoptions should now be thought of as final-session cash-deal instruments, not generic biotech exposure. - Residual extrinsic value can compress further as the market transitions from “live tender offer” to “final trading session before probable close.”
- The main reader value has shifted from takeover repricing into execution discipline and end-state contract awareness.
Still not confirmed by this Nasdaq alert
- No final OCC memo in this phase yet establishing the post-close options deliverable.
- No exchange notice here stating that options contracts have already been accelerated.
- No guarantee that the stated closing path cannot be extended, revised, or delayed.
That last point matters. An anticipated last trading day is a stronger operational signal than a generic merger timetable, but it is still not the same thing as a legally completed end state.
How this phase differs from the earlier NUVL coverage
The site’s June 9 GSK-Nuvalent announcement-phase article was mainly about takeover repricing, implied-volatility reset, and capped-upside logic after the acquisition terms became public.
The July 7 tender-offer article moved the story into a more mechanical phase by focusing on the live offer clock and OCC memo 59288.
The July 13 Nasdaq alert changes the reader lesson again. This is no longer mainly “the deal is live.” It is “the stock is expected to stop trading after tomorrow’s post-close session, so the remaining edge is procedural.” That is a real event-phase change for options traders even though the cash price itself has not changed.
What traders may misunderstand
“If the merger price is still USD 124, there is nothing new here”
Wrong. The cash consideration stayed the same, but the operational timeline got much tighter. A stated last trading day and halt schedule is new information for anyone managing options into the close.
“The halt schedule means the final OCC terms are already known”
No. Nasdaq handles the stock-trading timeline. OCC handles the contract mechanics for listed options. Those are related, but not identical, layers of the event.
“Once the halt is announced, assignment risk is gone”
No. Assignment risk exists until the position is closed, expires, or is otherwise transformed by the final contract terms. A merger name with thin extrinsic value can still create early-exercise or assignment decisions before the halt.
“This phase is just a duplicate of the July 7 tender-offer article”
No. The July 7 lesson was the live offer clock. The July 13 lesson is the expected last trading day, after-hours halt timing, and suspension path. Those are different operational questions.
Bottom line
Nasdaq has now moved Nuvalent into a tighter endgame window. NUVL is expected to have its last trading day on July 14, 2026, then be halted after the after-hours session at around 7:50 p.m. ET, with the merger tentatively set to close before the July 15 open and the stock slated for July 16 suspension if the transaction completes as planned.
For options traders, that makes this a final-session management story. The practical focus is no longer biotech narrative or even generic tender-offer math. It is whether you understand the shrinking time window, the remaining assignment risk, the likely liquidity friction, and the fact that the final OCC end-state memo may still be the next separate phase.
This article is not financial, investment, or trading advice. Options trading involves substantial risk, including event risk, liquidity risk, and the risk of misunderstanding corporate-action contract mechanics.
Sources
- Nasdaq Trader Equity Corporate Actions Alert #2026-493, “Information Regarding the Merger of Nuvalent, Inc. (NUVL)”:
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-493 - OCC Information Memo 59288, “Nuvalent, Inc. - Tender Offer”:
https://infomemo.theocc.com/infomemos?number=59288 - GSK tender-offer communication filed June 24, 2026:
https://www.sec.gov/Archives/edgar/data/1131399/000165495426006168/a6263j.htm - Nuvalent investor relations, “GSK enters agreement to acquire Nuvalent, Inc.”:
https://investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent%2C-Inc
